Tag: R-Pharm

R-Pharm localized full-cycle manufacturing of Glatirat

R-Pharm
Yaroslavl Plant of Finished Dosage Forms and Biotechnological Substances completed the project to localize the full-cycle manufacturing of Glatirat

R-Pharm and PrimeBioMed will develop a quantitative immunohistochemical test

research
R-Pharm Group and PrimeBioMed LLC signed an agreement on joint development of a quantitative immunohistochemical test for the use of drugs blocking PD-1/PD-L1

R-Pharm completes the deal to sell a 10% stake to Mitsui

pharma-deal
October 17 marked the closing of a deal on acquisition of a 10% stake in R-Pharm, a Russian pharmaceutical company, by Mitsui & Co., Ltd.

R-Pharm becomes the first Russian company to conduct clinical trials in South Korea

laboratory
A meeting with the doctors and employees of 8 leading South Korean clinical and university centers was held in Seoul.

A fund established by RDIF and JBIC invests in R-Pharm

dmitriev
The first deal of the joint investment fund established by Japan Bank for International Cooperation and Russian Direct Investment Fund will be investment in R-Pharm

R-Pharm will help to introduce innovative diagnostic methods in Kazakhstan

deal
On August 26, during the Eurasian Week held in Astana, ULNANOTECH, LLP R-Pharm Kazakhstan and LLC TestGen signed a cooperation agreement.

Phase III clinical study of Remimazolam starts in Russia

R-Pharm began the Phase III clinical study of the medicine used to induce and maintain the general anesthesia

Otsuka and R-Pharm sign a licensing agreement to market Deltyba

deal
Otsuka Pharmaceutical Co. Ltd. and R-Pharm Group signed a licensing agreement to manufacture and market Deltyba

R-Pharm and Aspyrian Therapeutics signed an exclusive licensing agreement

research
R-Pharm Overseas, Inc., a division of R-Pharm Group, signed an exclusive licensing agreement with Aspyrian Therapeutics Inc.

MSD and R-Pharm invested 200 million rubles in the localization of Raltegravir

r-pharm
MSD, an international biopharmaceutical company, and R-Pharm, a leading Russian pharmaceutical company, have announced the successful completion of their joint project

R-Pharm plans to launch its products onto the Japanese market

repik
In three years, the Russian pharmaceutical company R-Pharm intends to launch some of its medicines onto the Japanese market.

R-Pharm and Nacimbio established a joint venture

r-pharm-nacimbio
National Immunobiological Company, a part of Rostec Corporation, and R-Pharm, a Russian pharmaceutical company, signed an agreement to establish a joint venture.

New product of R-Pharm will reduce the cost of HCV treatment

r-pharm
On April 25, Vladimir Putin met the representatives of businesses in the Yaroslavl region. The event was attended by Vasily Ignatiev, the CEO of R-Pharm Group. The CEO of R-Pharm mentioned the suppor...

R-Pharm releases first batch of medicines with protective labeling

labelling
On March 14, ORTAT, a pharmaceutical plant of R-Pharm Group, released the first batch of Herceptin, a medicine, with DataMatrix code. 2D code on the package of the medicinal product fully complies wit...

R-Pharm and FUJIFILM Corporation Sign Agreement on Comprehensive Cooperation in the Field of Healthc...

R-Pharm group and FUJIFILM Corporation signed an agreement on healthcare cooperation on the sidelines of the Russian-Japanese dialogue within the visit of the President of the Russian Federation V.V. ...

The first Immuno-Oncology Drug of the Innovative PD-1 Inhibitor Class has been Approved in Russia

merck
MSD, known as Merck & Co. in the United States and Canada, informs that the first-in-class of the PD-1 inhibitors immuno-oncology drug, pembrolizumab, has been approved in Russia. This drug is ind...